Sanofi’s Dupixent and new drugs drive growth, despite near-term pressures. See why SFY stock’s product pipeline makes it a ...

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Sanofi (SNYNF – Research Report) today and set a price target of €105.00. The ...

SNY's reasonable valuation, improving top-line performance, contributions from new product launches and positive pipeline progress are good enough reasons to stay invested in the stock ...

Fifth Third Wealth Advisors LLC boosted its stake in Sanofi (NASDAQ:SNY – Free Report) by 27.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission.

Regeneron shares have been in a bearish trend since August, losing over one third of their value. Read why I am initiating ...

New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myelomaSarclisa SC formulation added to ...

As the J.P. Morgan Healthcare Conference enters its second day, we're tracking presentations from GSK, Novartis, Sanofi, Eli ...

DelveInsight's“Bullous Pemphigoid Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Bullous Pemphigoid, historical and forecasted epidemiology as ...

Middle East and Asia Injectable Drugs market 2025 To achieve a therapeutic effect in humans and animals, drug delivery is the method of delivering a Pharmaceutical compound. Mr. Shah Coherent Market ...

Sanofi possesses a leading vaccine portfolio that drives the top line. Several new drugs have ... in all key markets and lower sales from mature products are hurting sales. Other headwinds include ...